Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | PARP1 | P09874 | 3/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | QPCT | Q16769 | 1/20 | 0.43 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzimidazole SCHEMBL29218507 | 0.93 | MMP12 (0.47) | MMP12SMN1; SMN2PARP1PDPK1CA12 | |
| Benzimidazole SCHEMBL29408372 | 0.93 | — | — | |
| Benzimidazole SCHEMBL29358377 | 0.93 | — | — | |
| Benzimidazole SCHEMBL10931770 | 0.93 | SMN1; SMN2 (0.50) | MMP12SMN1; SMN2PARP1PDPK1CA12 | |
| Benzimidazole SCHEMBL461969 | 0.93 | SMN1; SMN2 (0.50) | MMP12SMN1; SMN2PARP1PDPK1CA12 | |
| Benzimidazole SCHEMBL6009 | 0.93 | — | — | |
| Benzimidazole SCHEMBL28471261 | 0.91 | SMN1; SMN2 (0.45) | MMP12SMN1; SMN2PARP1PDPK1CA12 | |
| Benzimidazole SCHEMBL5040740 | 0.91 | KDM4E (0.47) | MMP12SMN1; SMN2PARP1PDPK1CA12 | |
| Benzimidazole SCHEMBL23673327 | 0.91 | SMN1; SMN2 (0.48) | MMP12SMN1; SMN2PARP1PDPK1CA12 | |
| Benzimidazole SCHEMBL20531480 | 0.91 | SMN1; SMN2 (0.48) | MMP12SMN1; SMN2PARP1PDPK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107129489-A | A kind of preparation method of chiral phase-transfer catalyst | 武汉励合生物医药科技有限公司 | 2017-09-05 | — | — | CN | disclosed |
| US-9101628-B2 | Methods and composition of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| CN-102448458-B | Methods and compositions for treating flaviviridae virus infections | UNIV LELAND STANFORD JUNIOR | 2015-07-22 | — | — | CN | disclosed |
| US-8975247-B2 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| CN-102448458-A | Methods and compositions for treating flaviviridae virus infections | UNIV LELAND STANFORD JUNIOR | 2012-05-09 | — | — | CN | disclosed |
| EP-2408449-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010107739-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NSUN3, RNGTT, NSUN2 | MMP12 2162/4885SMN1; SMN2 3111/4885PARP1 3850/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | MMP12 1908/4885SMN1; SMN2 2247/4885PARP1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.